Asthma in Children, Chronic Diseases in Children
Conditions
Keywords
Digital Health
Brief summary
A randomized controlled trial with parent-child pairs of children with persistent or uncontrolled asthma. An intervention group (n=40 parent-child pairs) will receive the mobile health (mHealth) app and digital sensors with enhanced support from a population health manager role, hereinafter referred to as an asthma coordinator, to provide remote patient monitoring (RPM). A comparison group (n=40 parent-child pairs) will receive the mHealth app and sensors without RPM support to silently collect inhaler use information without mHealth app features. The focus of this project is to evaluate the feasibility and acceptability of delivering a digital intervention for pediatric asthma with RPM in the outpatient setting.
Interventions
The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.
Sponsors
Study design
Eligibility
Inclusion criteria
Inclusion into the study will not depend on sex, ethnicity, or race. We will monitor enrollment to ensure a diversity of sex and race/ethnicity are represented. PARENT-CHILD PAIR INCLUSION CRITERIA 1. Caregivers must be at least 18 years old (defined as parent or legal guardian) 2. The child (patient) has a diagnosis of asthma associated with a clinic visit in the electronic health record 3. The child is between the ages of 4-17 years old at the time of recruitment 1. The study is interested in the self-management of asthma by caregivers, whom are still primarily responsible for their child's chronic disease management. 2. Children younger than 4 years old will not be included in this study as the diagnosis of asthma is typically difficult to confirm in younger ages. 4. The child is prescribed inhaled corticosteroid or corticosteroid/long-acting beta agonist combination for daily use. The patient can have an inhaled corticosteroid/long-acting beta agonist for both daily preventive and rescue use, as in Single Maintenance and Reliever Therapy (SMART). 5. Persistent or un controlled asthma based on NHLBI guidelines40; Any 1 of the following: 1. In past month, \>2 days per week with asthma symptoms 2. \>2 days per week with rescue medication use 3. \>2 days per month with nighttime awakenings (for children who are not taking a controller asthma medication) OR \>2 days per month with nighttime awakenings (for children who are currently taking a controller asthma medication) 4. \>2 asthma episodes during the past year that required systemic corticosteroids 6. The child is a patient in Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH PARENT-CHILD PAIR
Exclusion criteria
1. The caregiver has a smartphone that is not compatible with the Hailie® app. 2. The patient is prescribed a controller (preventive) or rescue inhaler medication to which the Hailie electronic sensor cannot affix. 3. The caregiver is unable to speak and understand English. a. With this trial, the intent is to first establish feasibility and broaden to different languages in future. 4. The child has clinically significant, comorbid diagnoses, such as cystic fibrosis, cyanotic heart disease, or bronchopulmonary dysplasia, that could interact with their assessment of asthma-related measures. 5. The family has active Department of Child and Family Services (DCFS) involvement 6. The participant is enrolled in another asthma intervention study at the time of enrollment to this study. 7. Child or sibling living in the same home was previously enrolled in this study. 8. Consent is not obtained from the parent/guardian. 9. Parent/guardian does not pass the test of understanding at study enrollment. HEALTH CARE PROVIDER INCLUSION CRITERIA (IMPLEMENTATION OUTCOMES) 1. Participant is an employee of LCH system 2. Works at or supports the operations of Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH 3. Able to provide informed consent HEALTH CARE PROVIDER
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Study Feasibility | Baseline, 12 months | Measured as the number and percentage of participants who complete the 12-month visit, between intervention and comparison group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intervention Feasibility | 12 months | Measured as the number and percentage of participants who synced their ICS sensor \>80% of enrolled days in the trial, comparing intervention and comparison groups. |
| Asthma Symptom Control | Baseline, 1, 3, 6, 9, and 12 months. | Investigators will use the validated childhood Asthma Control Test (c-ACT) for assessing asthma symptom control, or Asthma Control Test (ACT) if the child becomes 12 years old during the study. |
| Inhaled Corticosteroid Adherence | Continuously through the 12 months | Investigators will compare overall raw ICS adherence rates between intervention and comparison groups using two-sample tests for proportions of mean daily proportion of taken doses over prescribed doses of ICS by study month, measured by digital sensors on the ICS. Participants' data will be included if they had at least 1 ICS inhaler actuation during the trial. |
Countries
United States